Study: Jin 2016, Cochrane Database of Systematic Reviews

Ganoderma lucidum (Reishi mushroom) for cancer treatment

Citation

Jin X, Ruiz Beguerie J, Sze DM, Chan GC (2016). Cochrane Database of Systematic Reviews. PubMed id 27045603.

Open on PubMed

Cards that cite this study (1)

Each card gives its own wording for who was tested, how and what was found.

  • Lion's mane and reishi mushroom supplements Tier B thin

    B Cancer patients in five randomised trials of reishi (Ganoderma lucidum), mostly as an add-on to chemotherapy or radiotherapy (n=5)

    Cochrane systematic review (searches to February 2016).

    Methodological quality was generally unsatisfying and reporting poor. People given reishi alongside chemotherapy or radiotherapy were more likely to respond than with the treatment alone (relative risk 1.50, 95% CI 0.90 to 2.51), and reishi on its own did not match that. No trial reported long-term survival, and adverse events were reported in only one study.

    As recorded in this card: Jin X, Ruiz Beguerie J, Sze DM, Chan GC (2016), Cochrane Database of Systematic Reviews, [review]

    Note: Cancer patients, not healthy people taking it for immunity. Quality poor.

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.